| Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions NS Vasudev, AR Reynolds Angiogenesis 17, 471-494, 2014 | 854 | 2014 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 456 | 2020 |
| (−)‐Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels Y Akbulut, HJ Gaunt, K Muraki, MJ Ludlow, MS Amer, A Bruns, ... Angewandte Chemie International Edition 54 (12), 3787-3791, 2015 | 222 | 2015 |
| Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models VL Bridgeman, PB Vermeulen, S Foo, A Bilecz, F Daley, E Kostaras, ... The Journal of pathology 241 (3), 362-374, 2017 | 212 | 2017 |
| Variation in genomic landscape of clear cell renal cell carcinoma across Europe G Scelo, Y Riazalhosseini, L Greger, L Letourneau, M Gonzàlez-Porta, ... Nature communications 5 (1), 5135, 2014 | 210 | 2014 |
| Diabetes and lower-limb amputations in the community: a retrospective cohort study AD Morris, R McAlpine, D Steinke, DIR Boyle, AR Ebrahim, N Vasudev, ... Diabetes Care 21 (5), 738-743, 1998 | 207 | 1998 |
| Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer NS Vasudev, M Wilson, GD Stewart, A Adeyoju, J Cartledge, M Kimuli, ... BMJ open 10 (5), e035938, 2020 | 121 | 2020 |
| Renal cancer biomarkers: the promise of personalized care NS Vasudev, PJ Selby, RE Banks BMC medicine 10, 1-10, 2012 | 88 | 2012 |
| Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein SPK Jagdev, W Gregory, NS Vasudev, P Harnden, S Sim, D Thompson, ... British journal of cancer 103 (11), 1649-1656, 2010 | 88 | 2010 |
| Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells M Gourlaouen, JC Welti, NS Vasudev, AR Reynolds Journal of Biological Chemistry 288 (11), 7467-7480, 2013 | 86 | 2013 |
| Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma SH Sim, MP Messenger, WM Gregory, TC Wind, NS Vasudev, J Cartledge, ... British journal of cancer 107 (7), 1131-1137, 2012 | 84 | 2012 |
| Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer SL Wood, M Rogers, DA Cairns, A Paul, D Thompson, NS Vasudev, ... British journal of cancer 103 (1), 101-111, 2010 | 65 | 2010 |
| Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma M Arseneault, J Monlong, NS Vasudev, RS Laskar, M Safisamghabadi, ... Scientific Reports 7 (1), 44876, 2017 | 60 | 2017 |
| Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An open-label, non … JE Brown, KL Royle, W Gregory, C Ralph, A Maraveyas, O Din, T Eisen, ... The Lancet Oncology 24 (3), 213-227, 2023 | 59 | 2023 |
| Delay in the diagnosis of testicular tumours—changes over the past 18 years NS Vasudev, JK Joffe, C Cooke, F Richards, WG Jones British journal of general practice 54 (505), 595-597, 2004 | 58 | 2004 |
| (−)-Englerin A-evoked cytotoxicity is mediated by Na+ influx and counteracted by Na+/K+-ATPase MJ Ludlow, HJ Gaunt, HN Rubaiy, KE Musialowski, NM Blythe, ... Journal of Biological Chemistry 292 (2), 723-731, 2017 | 54 | 2017 |
| Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy NS Vasudev, V Goh, JK Juttla, VL Thompson, JMG Larkin, M Gore, ... British journal of cancer 109 (5), 1230-1242, 2013 | 54 | 2013 |
| Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma NS Vasudev, S Sim, DA Cairns, RE Ferguson, RA Craven, A Stanley, ... British journal of cancer 101 (7), 1175-1182, 2009 | 52 | 2009 |
| Transient receptor potential canonical 4 and 5 proteins as targets in cancer therapeutics HJ Gaunt, NS Vasudev, DJ Beech European Biophysics Journal 45, 611-620, 2016 | 49 | 2016 |
| Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma VL Bridgeman, E Wan, S Foo, MR Nathan, JC Welti, S Frentzas, ... Molecular cancer therapeutics 15 (1), 172-183, 2016 | 48 | 2016 |
Andrew R ReynoldsAstraZeneca, ICR, BCI, CRUK LRICorreu electrònic verificat a astrazeneca.com